Indeed, the percentage of PD-L1 expression in tumor tissue has been shown to predict response to ICIs as monotherapy, especially in the first-line setting of NSCLC (p < 0.001) [11,12]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.